ERBB2 and Hodgkins lymphoma: There have been successful ADCs approved for other cancers such as trastuzumab emtansine for HER2-amplified breast and gastric cancers7, fam-trastuzumab deruxtecan-nxki for metastatic HER2-positive breast cancer8, brentuximab vedotin for CD30-positive Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphomas9.